When thinking of a biotech market mover Paradigm Biopharmaceuticals (ASX: PAR) instantly comes to mind. Paradigm, through its repurposed drug Zilosul, aims to alleviate the suffering and cartilage degradation of Osteoarthritis. PAR’s impressive clinical developments in osteoarthritis and 240% surge in 2019 captivated both the scientific and investment world. Paradigm kickstarted 2020 off with a […]
Tag Archives: Australian Financial Review
Tesla predicted to hit $7000 by 2024 says ARK Investment Management
Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. Tesla’s recent share price surge may only be the start, according to ARK Investment Management. A recent price target set by ARK shows some very opportunistic views on Tesla’s future […]
An $800 investment in Amazon at IPO would now be worth over $1,000,000
Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. Amazon is currently priced at $1,861.64 (AMZN), a 120,000% price increase since it’s IPO in 1997. Amazon’s come up is nothing short of remarkable, with the distribution giant reaching $1 […]
Cann Group losing value as bearish market trend sets in – How much more will investors take?
Before I start, I am obliged to remind our viewers that this is not advice only general commentary from my extensive research in this area. Introduction Cann Group (CAN) Cann Group (CAN) is an Australian medicinal cannabis company. Cann aims to research, cultivate, and manufacture a range for medicinal cannabis products for patients in Australia […]